Search

Now showing items 1-10 of 31

Phase II trial of ZD0473 as second-line therapy in mesothelioma

Giaccone G.; O'Brien M.E.R.; Byrne M.J.; Bard M.; Kaukel E.; Smit B. (2002)

A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural mesothelioma has been completed. The objectives were to evaluate the activity and tolerability ...

Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis

Schneider, H.; Van Rensburg, C.; Schmidt, S.; Aboo, N.; Makela, H.; Naucler, E.; Hallerback, B.; Svedberg, L-E. (2004)

Background/Aims: An intravenous formulation of esomeprazole has been developed for use in patients where oral administration is not appropriate. This study evaluated safety after 1 and 4 weeks, and efficacy after 4 weeks' ...

Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

Bardhan K.D.; Van Rensburg C. (2001)

Background: Several clinical trials have shown that pantoprazole (40 mg) and omeprazole (40 or 20 mg) have similar efficacy and safety in the treatment of grade II-IV reflux oesophagitis (Savary-Miller classification). ...

Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease

Van Zyl J.; Van Rensburg C.; Vieweg W.; Fischer R. (2004)

Background/Aim: Gastroesophageal reflux disease (GERD) is a prevalent disease associated with a high symptom burden and a reduced quality of life. This multicenter, randomized, double-blind study compared relief from key ...

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

Stryjewski M.E.; Chu V.H.; O'Riordan W.D.; Warren B.L.; Dunbar L.M.; Young D.M.; Vallee M.; Fowler Jr. V.G.; Morganroth J.; Barriere S.L.; Kitt M.M.; Corey G.R. (2006)

Telavancin is a bactericidal lipoglycopeptide with a multifunctional mechanism of action. We conducted a randomized, double blind, active-control phase II trial. Patients S18 years of age with complicated skin and skin ...

Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia

Stein E.A.; Amerena J.; Ballantyne C.M.; Brice E.; Farnier M.; Guthrie R.M.; Harats D.; Ma P.T.S.; Le Maulf F.; Melezinkova H.; Gold A.; Sager P. (2007)

Patients with elevated low-density lipoprotein (LDL) cholesteral levels are at high risk of cardiovascular events but are often undertreated and fail to achieve lipid goals. This open-label, noncomparative, multicenter ...

Intragastric pH during Continuous Infusion with Pantoprazole in Patients with Bleeding Peptic Ulcer

Van Rensburg C.J.; Hartmann M.; Thorpe A.; Venter L.; Theron I.; Luhmann R.; Wurst W. (2003)

OBJECTIVES: In managing patients with bleeding peptic ulcers, prevention of rebleeding is a particular challenge to hemostasis and fibrinolysis, both of which involve reactions that are impaired in acidic gastric environment. ...

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin

Yeomans N.; Lanas A.; Labenz J.; Van Zanten S.V.; Van Rensburg C.; Racz I.; Tchernev K.; Karamanolis D.; Roda E.; Hawkey C.; Naucler E.; Svedberg L.-E. (2008)

OBJECTIVES: Low-dose aspirin is standard treatment for prevention of cardiovascular events in at-risk patients. However, long-term administration of low-dose aspirin is associated with a greater risk of adverse events, ...

Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia

Jacobs P.; Wood L. (2005)

Cytosine arabinoside and anthracycline-containing regimens induce remission in upwards of 60% of previously untreated patients with adult acute myeloid leukaemia (AML). Despite this, in addition to primary drug resistance, ...

No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease

Van Rensburg C.J.; Bardhan K.D. (2001)

Objective Although a proton pump inhibitor (PPI) and a prokinetic drug are often combined for the medical treatment of gastro-oesophageal reflux disease (GORD), there are few well-conducted clinical studies on the efficacy ...